Item 5. Other Information
Item
5. Other Information.
None.
24
Item
6. Exhibits
The
following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
No.
Description
of Exhibit
2.1*
Amendment No. 1 to Business Combination Agreement, dated September 6, 2022, among Deep Medicine Acquisition Corp., Chijet Inc., Chijet Motor Company, Inc., Chijet Motor (USA) Company, Inc. and the Sellers named therein (holding in excess of 50% of Chijet’s outstanding shares) (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 12, 2022).
2.2*
Amendment No. 2 to Business Combination Agreement, dated September 16, 2022, among Deep Medicine Acquisition Corp., Chijet Inc., Chijet Motor Company, Inc., Chijet Motor (USA) Company, Inc. and the Sellers named therein (holding in excess of 50% of Chijet’s outstanding shares). (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 20, 2022).
2.3
Business Combination Agreement, dated July 12, 2022, among Deep Medicine Acquisition Corp., Chijet Inc., Chijet Motor Company, Inc., Chijet Motor (USA) Company, Inc. and the Sellers named therein (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on July 18, 2022).
2.4
Support Agreement dated July 12, 2022, among Deep Medicine Acquisition Corp., Bright Vision Sponsor LLC, Chijet Inc. and Chijet Motor Company, Inc. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on July 18, 2022).
10.1
Form of Promissory Note issued on October 15, 2022. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 20, 2022).
31.1**
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2**
Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1***
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2***
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS**
Inline XBRL Instance Document
101.SCH**
Inline XBRL Taxonomy Extension
Schema Document
101.CAL**
Inline XBRL Taxonomy Extension
Calculation Linkbase Document
101.DEF**
Inline XBRL Taxonomy Extension
Definition Linkbase Document
101.LAB**
Inline XBRL Taxonomy Extension
Labels Linkbase Document
101.PRE**
Inline XBRL Taxonomy Extension
Presentation Linkbase Document
104**
Cover Page Interactive
Data File.
*
Certain of the exhibits,
appendices, annexes and/or schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant
agrees to furnish supplementally a copy of all omitted exhibits, annexes, appendices and schedules to the Securities and Exchange
Commission upon its request.
**
Filed herewith.
***
Furnished herewith.
25
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
DEEP MEDICINE ACQUISITION CORP.
Date: November 14, 2022
By:
/s/ Humphrey
P. Polanen
Name:
Humphrey P. Polanen
Title:
Chief Executive Officer
(Principal Executive Officer)
Date: November 14, 2022
By:
/s/ Weixuan
Luo
Name:
Weixuan Luo
Title:
Chief Financial Officer
(Principal Financial and Accounting Officer)
26
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.